Primary endpoint
Clinical remission at week 12.
phase 2 · Recruiting
Phase 2 induction study of BPC-612 in ulcerative colitis
Randomized, double-blind, placebo-controlled Phase 2 induction study of BPC-612 in moderate to severe ulcerative colitis.
Investigational candidate. BPC-612 has not been approved by any regulatory authority.
Enrollment
Patient participation.
Enrolled 95
Target 180
Sites 5
53% of target enrollment reached.
Design
Trial endpoints.
Secondary endpoints
- Endoscopic improvement
- Histologic remission
- Safety
Eligibility
Adults with moderate to severe ulcerative colitis with inadequate response or intolerance to conventional therapy.
Timeline
- Started
- November 1, 2024
Sites
5 sites for NCT-BPC612-201.
- Basel, Switzerland
Basel Research Laboratory
Grenzacherstrasse 250, 4058 Basel
- Zurich, Switzerland
University Hospital Zurich
Rämistrasse 100, 8091 Zürich
- London, United Kingdom
London Cancer Institute
250 Euston Road, London NW1 2PG
- Madrid, Spain
Madrid Clinical Network
Calle de Alfonso XII 64, 28014 Madrid
- Toronto, Canada
Toronto Health Network
200 Elizabeth Street, Toronto, ON M5G 2C4